DCSIMG
Treat Your Patients Insomnia with AMBIEN CR® (zolpidem tartrate)

Insomnia & Your Patients

In order to help you understand your patients’ sleep problems and treat them more effectively, we have assembled some background information on insomnia, how it affects your patients, and how they perceive sleep problems and their treatment.

Epidemiology & Prevalence of Insomnia

How insomnia is affecting Americans, and how patients are choosing to treat their sleep problems.

Go

Co-morbidity of Insomnia

There is a common association between insomnia and Generalized Anxiety Disorder (GAD)14-17and Major Depressive Disorder (MDD).14-16,18,19

Go

Insomnia Patient Discussion Guide

Some useful insights to help prepare you to speak with your patients about insomnia and work together on a course of action.

Go

Next: Epidemiology & Prevalence of Insomnia

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. AMBIEN CR is not indicated for the treatment of GAD or MDD.

Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep.

IMPORTANT SAFETY INFORMATION

Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. Therefore, AMBIEN CR should be administered with caution to patients exhibiting signs or symptoms of depression, in whom suicidal tendencies may be present and protective measures may be required. Intentional overdosage is more common in this group of patients; the least amount of drug that is feasible should be prescribed for the patient at any one time.The most commonly observed adverse events in controlled clinical trials were headache, somnolence, and dizziness.

Please refer to the full prescribing information.